National mass drug administration costs for lymphatic filariasis elimination.

• Main Authors: Ann S Goldman (Author), Victoria H Guisinger (Author), Moses Aikins (Author), Maria Lourdes E Amarillo (Author), Vicente Y Belizario (Author), Bertha Garshong (Author), John Gyapong (Author), Conrad Kabali (Author), Hussein A Kamal (Author), Sanjat Kanjilal (Author), Dominique Kyelem (Author), Jefrey Lizardo (Author), Mwele Malecela (Author), Godfrey Mubyazi (Author), P Abdoulaye Nitièma (Author), Reda M R Ramzy (Author), Thomas G Streit (Author), Aaron Wallace (Author), Molly A Brady (Author), Richard Rheingans (Author), Eric A Ottesen (Author), Anne C Haddix (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2007-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BACKGROUND: Because lymphatic filariasis (LF) elimination efforts are hampered by a dearth of economic information about the cost of mass drug administration (MDA) programs (using either albendazole with diethylcarbamazine [DEC] or albendazole with ivermectin), a multicenter study was undertaken to...